The news sent the company’s stock to its lowest level since March 2009. NeurogesX hasn’t reported a profit since the company began selling shares in 2007, and the stock has fallen 83 percent in the past year.
Advisors are scheduled to meet with regulators tomorrow, and a final decision is expected by March 7.
Related Articles on Pain Management:
Study: Spinal Cord Stimulation Effective for HIV Neuropathy
Pain Center of Arizona Opens New Clinic in Phoenix
Pain Physicians: What is the Biggest Factor Contributing to Your Practice’s Profitability?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.